hackint0sh/temp-data huggingface dataset:
protocolSection identificationModule nctId: NCT06294795, orgStudyIdInfo id: 2-2024, briefTitle: Toric Intraocular Lens Implantation in Pediatric Cataract, acronym: TILIPC, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-03-01, primaryCompletionDateStruct date: 2024-12-31, completionDateStruct date: 2025-12-31, studyFirstPostDateStruct date: 2024-03-06, lastUpdatePostDateStruct date: 2024-03-15, sponsorCollaboratorsModule leadSponsor name: Kazakh Eye Research Institute, class: NETWORK, descriptionModule briefSummary: To evaluate the visual and refractive outcomes after an intraocular lens (IOL) implantation in pediatric eyes with cataract and preexisting corneal astigmatism, conditionsModule conditions: Cataract Congenital, conditions: Astigmatism, conditions: IOL, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: DOUBLE, whoMasked: PARTICIPANT, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 40, type: ESTIMATED, armsInterventionsModule interventions name: congenital/pediatric cataract surgery, interventions name: Non-Toric IOLs, interventions name: Toric IOLs, outcomesModule primaryOutcomes measure: Uncorrected (UCDVA) and corrected (CDVA) distance visual acuity, primaryOutcomes measure: Uncorrected (UCNVA) and corrected (CNVA) near visual acuity, primaryOutcomes measure: Refraction measurements, secondaryOutcomes measure: Keratometry measurements, eligibilityModule sex: ALL, minimumAge: 6 Years, maximumAge: 18 Years, stdAges: CHILD, stdAges: ADULT, contactsLocationsModule locations facility: Kazakh Eye Research Institute, status: RECRUITING, city: Almaty, zip: 050012, country: Kazakhstan, contacts name: Kairat Ruslanuly, MD, role: CONTACT, phone: +77019008387, email: ruslanuly.kairat@gmail.com, contacts name: Zhansaya Sultanbayeva, MD, role: CONTACT, phone: +77023777735, email: sultanbayeva.zhansaya@gmail.com, contacts name: Lukpan Orazbekov, MD, role: PRINCIPAL_INVESTIGATOR, contacts name: Kairat Ruslanuly, MD, role: SUB_INVESTIGATOR, contacts name: Zhansaya Sultanbayeva, MD, role: SUB_INVESTIGATOR, contacts name: Meruert Ashimova, MD, role: SUB_INVESTIGATOR, geoPoint lat: 43.25667, lon: 76.92861, locations facility: Kazakh Eye Research Institute, status: RECRUITING, city: Astana, zip: 010000, country: Kazakhstan, contacts name: Gulnaz Kassymbekova, MD, role: CONTACT, phone: +77478538289, email: GulnazKassymbekova@gmail.com, contacts name: Asiya Beisebayeva, MD, role: CONTACT, phone: +77018333953, contacts name: Aigerim Tuletova, MD, role: PRINCIPAL_INVESTIGATOR, contacts name: Asiya Beisebayeva, MD, role: SUB_INVESTIGATOR, contacts name: Gulnaz Kassymbekova, MD, role: SUB_INVESTIGATOR, geoPoint lat: 51.1801, lon: 71.44598, hasResults: False
protocolSection identificationModule nctId: NCT06294782, orgStudyIdInfo id: 36/2022, briefTitle: PrOsPective Cohort Study for STereotactic Arhythmia Radioablation (STAR) of Refractory Ventricular Tachycardia, acronym: POPSTAR, statusModule overallStatus: RECRUITING, startDateStruct date: 2022-04-15, primaryCompletionDateStruct date: 2025-02, completionDateStruct date: 2025-02, studyFirstPostDateStruct date: 2024-03-06, lastUpdatePostDateStruct date: 2024-03-06, sponsorCollaboratorsModule leadSponsor name: University of Turin, Italy, class: OTHER, collaborators name: Azienda Unità Sanitaria Locale Reggio Emilia, collaborators name: IRCCS Sacro Cuore Don Calabria di Negrar, collaborators name: Fondazione IRCCS Policlinico San Matteo di Pavia, descriptionModule briefSummary: This is a multicenter, interventional study. The study will enroll patients that fulfill the inclusion criteria over a 33-month period. Considering the small number of patients who will meet the study criteria, it is also possible to include retrospective patients who already underwent STAR (for instance, as part of a compassionate program) if they meet all the inclusion and exclusion criteria as well as the treatment planning standardized requirements and sign their consent to this trial. All patients prospectively enrolled will undergo a flow of investigations following a standardized approach. ICD programming will be standardized., conditionsModule conditions: Refractory Ventricular Tachycardia, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 30, type: ESTIMATED, armsInterventionsModule interventions name: STereotactic Arhythmia Radioablation (STAR), outcomesModule primaryOutcomes measure: VT storm and incessant VT, primaryOutcomes measure: adverse events, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 85 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: University of Turin, status: RECRUITING, city: Turin, country: Italy, contacts name: Gaetano Maria De Ferrari, role: CONTACT, geoPoint lat: 45.07049, lon: 7.68682, hasResults: False
protocolSection identificationModule nctId: NCT06294743, orgStudyIdInfo id: C202304001, briefTitle: Posterior Tibia Nerve Neuroprolotherapy for Dysmenorrhea, statusModule overallStatus: RECRUITING, startDateStruct date: 2023-11-23, primaryCompletionDateStruct date: 2025-12-31, completionDateStruct date: 2025-12-31, studyFirstPostDateStruct date: 2024-03-06, lastUpdatePostDateStruct date: 2024-03-06, sponsorCollaboratorsModule leadSponsor name: Taichung Armed Forces General Hospital, class: OTHER_GOV, descriptionModule briefSummary: The goal of this crossover study is to assessed the treatment efficacy of posterior tibia nerve neuroprolotherapy on dysmenorrhea. The primary outcome is the improvement of Visual Analogue Scale. The main question it aims to answer is:•Could the posterior tibial nerve neuroprolotherapy alleviate the pain of dysmenorrhea.Participants will be randomly allocated into two groups, Group-1 will receive neuroprolotherapy in the first 2 menstrual cycles followed by oral acetaminophen(500mg) for the subsequent 2 menstrual cycles. Group02 will received oral acetaminophen(500mg) in initial 2 menstrual cycles, followed by receiving neuroprolotherapy for the subsequent 2 menstrual cycles., conditionsModule conditions: Dysmenorrhea, conditions: Prolotherapy, designModule studyType: INTERVENTIONAL, phases: EARLY_PHASE1, designInfo allocation: RANDOMIZED, interventionModel: CROSSOVER, interventionModelDescription: Group-1, posterior tibial nerve neuroprolotherapy will be administered during the first two menstrual cycles, followed by oral acetaminophen (500mg) for the subsequent two menstrual cycles. Conversely.Group-2, oral acetaminophen (500mg) will be given during the initial two menstrual cycles, followed by a transition to posterior tibial nerve neuroprolotherapy for the last two menstrual cycles., primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 60, type: ESTIMATED, armsInterventionsModule interventions name: Posterior tibial nerve neuroprolotherapy, interventions name: Acetaminophen 500Mg Tab, outcomesModule primaryOutcomes measure: Visual Analogue Scale, secondaryOutcomes measure: The SF-36v2® Health Survey, eligibilityModule sex: FEMALE, minimumAge: 18 Years, maximumAge: 50 Years, stdAges: ADULT, contactsLocationsModule locations facility: Taichung Armed Forces General Hospital, status: RECRUITING, city: Taichung, state: Other (Non US), zip: 41168, country: Taiwan, contacts name: Jing-dung Shen, MD, role: CONTACT, phone: +886958878129, email: jdwhydo@gmail.com, contacts name: Jing-dung Shen, MD, role: PRINCIPAL_INVESTIGATOR, geoPoint lat: 24.1469, lon: 120.6839, hasResults: False
protocolSection identificationModule nctId: NCT06294717, orgStudyIdInfo id: AtaturkUPhStudentNeslihanATLI, briefTitle: The Effect of Progressive Relaxation Exercises on Physiological Parameters, Pain and Anxiety After Cesarean Section, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-03-01, primaryCompletionDateStruct date: 2024-08-01, completionDateStruct date: 2024-12-01, studyFirstPostDateStruct date: 2024-03-05, lastUpdatePostDateStruct date: 2024-03-05, sponsorCollaboratorsModule leadSponsor name: Ataturk University, class: OTHER, descriptionModule briefSummary: Caesarean section is a surgical procedure that can be performed before or during birth in cases where the life of the mother and fetus is threatened or upon the request of the mother and father. One of the most common problems after cesarean section is abdominal pain. Progressive relaxation exercises are a method that allows certain muscle groups in the body to first contract and then relax. Progressive relaxation exercises have been proven to have positive effects on anxiety. By applying progressive relaxation exercises, the parasympathetic nervous system is activated; Thus, heart and respiratory rate and blood pressure can be kept within normal limits. This study will be conducted to determine the physiological parameters, pain and anxiety levels of progressive relaxation exercises, one of the non-pharmacological methods, on women giving birth by cesarean section., conditionsModule conditions: Pain, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: SUPPORTIVE_CARE, maskingInfo masking: SINGLE, whoMasked: PARTICIPANT, enrollmentInfo count: 2, type: ESTIMATED, armsInterventionsModule interventions name: Progressive relaxation exercises will be applied., outcomesModule primaryOutcomes measure: Beck Anxiety Scale, secondaryOutcomes measure: Visual Analog Scale (VAS), eligibilityModule sex: FEMALE, minimumAge: 20 Years, maximumAge: 35 Years, stdAges: ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06294704, orgStudyIdInfo id: 2024/0004, briefTitle: Hybrid Closed Loop Insulin Pump and Bariatric Surgery in Patients With Type 1 Diabetes, acronym: PompBariatDT1, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-05-01, primaryCompletionDateStruct date: 2024-12-31, completionDateStruct date: 2024-12-31, studyFirstPostDateStruct date: 2024-03-05, lastUpdatePostDateStruct date: 2024-04-08, sponsorCollaboratorsModule leadSponsor name: Centre Hospitalier Sud Francilien, class: OTHER, descriptionModule briefSummary: Bariatric surgery is increasingly performed on patients with type 1 diabetes. It exposes these patients to an increased risk of hypoglycemia, including severe hypoglycemia, and of severe episodes of hyperglycemia, beyond the perioperative period. The long-term efficacy and safety of hybrid closed-loop insulin pump in these patients has not yet been published., conditionsModule conditions: Bariatric Surgery, conditions: Type 1 Diabetes, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: RETROSPECTIVE, enrollmentInfo count: 20, type: ESTIMATED, armsInterventionsModule interventions name: bariatric surgery, outcomesModule primaryOutcomes measure: time spent within glycemic target 70-180 mg/dL, secondaryOutcomes measure: Time spent in level 1 hyperglycemia (181-250 mg/dL), secondaryOutcomes measure: Time spent in level 2 hyperglycemia (>250 mg/dL), secondaryOutcomes measure: HbA1c, secondaryOutcomes measure: Coefficient of variation, secondaryOutcomes measure: Time spent in level 1 hypoglycemia (51-70 mg/dl), secondaryOutcomes measure: Time spent in level 2 hypoglycemia (< 50 mg/gdl), eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Centre Hospitalier Sud Francilien, city: Corbeil-Essonnes, zip: 91106, country: France, contacts name: Caroline TOURTE, role: CONTACT, phone: +33161693150, email: caroline.tourte@chsf.fr, geoPoint lat: 48.60603, lon: 2.48757, hasResults: False
protocolSection identificationModule nctId: NCT06294691, orgStudyIdInfo id: infusion time & aGVHD-002, briefTitle: Effect of Stem Cell Infusion Time on aGVHD in Patients With Nonmalignant Hematologic Diseases, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-03-01, primaryCompletionDateStruct date: 2025-11-30, completionDateStruct date: 2026-08-31, studyFirstPostDateStruct date: 2024-03-05, lastUpdatePostDateStruct date: 2024-03-05, sponsorCollaboratorsModule leadSponsor name: Anhui Provincial Hospital, class: OTHER_GOV, descriptionModule briefSummary: To observe the effect of stem cell infusion on the development of acute graft- versus-host disease (aGVHD) in patients with nonmalignant hematologic diseases after allogeneic peripheral blood hematopoietic stem cell transplantation (allo-PBSCT), conditionsModule conditions: Acute Graft-versus-host Disease, designModule studyType: INTERVENTIONAL, phases: PHASE3, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: PREVENTION, maskingInfo masking: NONE, enrollmentInfo count: 198, type: ESTIMATED, armsInterventionsModule interventions name: Time of stem cell infusion, outcomesModule primaryOutcomes measure: The cumulative incidence of grade III to IV aGVHD, secondaryOutcomes measure: The cumulative incidence of grade II to IV aGVHD, secondaryOutcomes measure: The cumulative incidence of neutrophil engraftment at 28 days after transplantation, secondaryOutcomes measure: The cumulative incidence of platelet recovery at 100 days after transplantation, secondaryOutcomes measure: The cumulative incidence of transplant-related mortality at 180 days after transplantation, secondaryOutcomes measure: The cumulative incidence of transplant-related mortality at 360 days after transplantation, secondaryOutcomes measure: The cumulative incidence of chronic GVHD at 360 days after transplantation, secondaryOutcomes measure: The probability of GVHD-free, relapse-free survival(GRFS), secondaryOutcomes measure: The probability of disease-free survival(DFS), secondaryOutcomes measure: The probability of overall survival(OS), eligibilityModule sex: ALL, minimumAge: 12 Years, maximumAge: 60 Years, stdAges: CHILD, stdAges: ADULT, contactsLocationsModule locations facility: The First Affiliated Hospital of University of Science and Technology of China (Anhui Provincial Hospital), city: Hefei, state: Anhui, zip: 230036, country: China, geoPoint lat: 31.86389, lon: 117.28083, hasResults: False
protocolSection identificationModule nctId: NCT06294678, orgStudyIdInfo id: infusion time & aGVHD-001, briefTitle: Effect of Stem Cell Infusion Time on aGVHD in Patients With Hematological Malignancies, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-03-01, primaryCompletionDateStruct date: 2025-11-30, completionDateStruct date: 2026-08-31, studyFirstPostDateStruct date: 2024-03-05, lastUpdatePostDateStruct date: 2024-03-05, sponsorCollaboratorsModule leadSponsor name: Anhui Provincial Hospital, class: OTHER_GOV, descriptionModule briefSummary: To observe the effect of stem cell infusion on the development of acute graft-versus-host disease (aGVHD) in patients with malignant hematologic diseases after allogeneic peripheral blood hematopoietic stem cell transplantation (allo-PBSCT), conditionsModule conditions: Acute Graft-versus-host Disease, designModule studyType: INTERVENTIONAL, phases: PHASE3, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: PREVENTION, maskingInfo masking: NONE, enrollmentInfo count: 198, type: ESTIMATED, armsInterventionsModule interventions name: Time of stem cell infusion, outcomesModule primaryOutcomes measure: The incidence of grade III to IV aGVHD, secondaryOutcomes measure: The incidence of grade II to IV aGVHD, secondaryOutcomes measure: The cumulative incidence of neutrophil engraftment at 28 days after transplantation, secondaryOutcomes measure: The cumulative incidence of platelet recovery at 100 days after transplantation, secondaryOutcomes measure: The cumulative incidence of transplant-related mortality at 180 days after transplantation, secondaryOutcomes measure: The cumulative incidence of transplant-related mortality at 360 days after transplantation, secondaryOutcomes measure: The cumulative incidence of chronic GVHD at 360 days after transplantation, secondaryOutcomes measure: The probability of GVHD-free, relapse-free survival(GRFS), secondaryOutcomes measure: The probability of disease-free survival(DFS), secondaryOutcomes measure: The probability of overall survival(OS), eligibilityModule sex: ALL, minimumAge: 12 Years, maximumAge: 60 Years, stdAges: CHILD, stdAges: ADULT, contactsLocationsModule locations facility: The First Affiliated Hospital of University of Science and Technology of China (Anhui Provincial Hospital), city: Hefei, state: Anhui, zip: 230036, country: China, geoPoint lat: 31.86389, lon: 117.28083, hasResults: False
protocolSection identificationModule nctId: NCT06294665, orgStudyIdInfo id: MD113/2023, briefTitle: Comparison Between Bupivacaine-Dexmedetomidine Versus Bupivacaine-Dexamethasone in Pericapsular Nerve Group (PENG) Block, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-03-01, primaryCompletionDateStruct date: 2024-12-01, completionDateStruct date: 2025-01-01, studyFirstPostDateStruct date: 2024-03-05, lastUpdatePostDateStruct date: 2024-03-05, sponsorCollaboratorsModule leadSponsor name: Ain Shams University, class: OTHER, descriptionModule briefSummary: The aim of this work is to compare the effectiveness of bupivacaine- dexmedetomidine mixture versus bupivacaine-dexamethasone mixture in PENG Block as Post-operative Analgesia in Hip surgeries, conditionsModule conditions: Hip Fractures, conditions: Post Operative Pain, designModule studyType: INTERVENTIONAL, phases: PHASE1, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 60, type: ESTIMATED, armsInterventionsModule interventions name: Pericapsular Nerve Group (PENG) Block, outcomesModule primaryOutcomes measure: The time to the first request of analgesia, secondaryOutcomes measure: Total doses of analgesia (Nalbuphine) given to patients in 24 hours postoperatively, secondaryOutcomes measure: Occurrence of side effects of drugs., eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 65 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Ain Shams University, status: RECRUITING, city: Cairo, zip: 11122, country: Egypt, contacts name: Fatma Ebeid, role: CONTACT, phone: +201095569596, email: dr.fatma_ebeid@yahoo.com, contacts name: Mohamed Salama, role: PRINCIPAL_INVESTIGATOR, geoPoint lat: 30.06263, lon: 31.24967, hasResults: False
protocolSection identificationModule nctId: NCT06294639, orgStudyIdInfo id: XJA-20240224, briefTitle: ED50 of Esketamine for Laser Treatment in Children, acronym: ESCALATE, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-03-27, primaryCompletionDateStruct date: 2025-03-27, completionDateStruct date: 2025-04-27, studyFirstPostDateStruct date: 2024-03-05, lastUpdatePostDateStruct date: 2024-03-05, sponsorCollaboratorsModule leadSponsor name: Air Force Military Medical University, China, class: OTHER, descriptionModule briefSummary: There is limited research on the combined use of esketamine and alfentanil for anesthesia during facial laser treatment in pediatric patients, and the effective dosage of esketamine for inhibiting body movement remains unclear. We explore the effective dose of esketamine combined with alfentanil for the inhibition of body movement during facial laser treatment in pediatric patients., conditionsModule conditions: Anesthesia, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NA, interventionModel: SEQUENTIAL, interventionModelDescription: The Biased coin method is used, primaryPurpose: OTHER, maskingInfo masking: NONE, maskingDescription: Esketamine will be prepared by an investigator who is not involved in anesthesia and outcome assessment. For all participants, esketamine will be diluted to the same volume., enrollmentInfo count: 40, type: ESTIMATED, armsInterventionsModule interventions name: Esketamine, outcomesModule primaryOutcomes measure: half effective dose of inhibition of body movement, secondaryOutcomes measure: number of patients with agitation during awake, secondaryOutcomes measure: number of patients with dizzy during awake, secondaryOutcomes measure: number of patients with nausea and vomiting during awake, secondaryOutcomes measure: number of patients with apnea during awake, secondaryOutcomes measure: satisfaction score of the parents to the anesthesia, eligibilityModule sex: ALL, minimumAge: 3 Years, maximumAge: 12 Years, stdAges: CHILD, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06294626, orgStudyIdInfo id: ISozeri, briefTitle: Examination of Neuromotor Development of Cases Diagnosed With Scaphocephaly, statusModule overallStatus: COMPLETED, startDateStruct date: 2019-01-01, primaryCompletionDateStruct date: 2023-12-31, completionDateStruct date: 2023-12-31, studyFirstPostDateStruct date: 2024-03-05, lastUpdatePostDateStruct date: 2024-03-05, sponsorCollaboratorsModule leadSponsor name: Acıbadem Atunizade Hospital, class: OTHER, descriptionModule briefSummary: It's an observational study. Purpose of the study: To evaluate the neuromotor development of scaphocephaly cases.21 infants diagnosed with scaphocephaly aged 2-17 months were included.* Is there any delay in the neuromotor development of scaphocephaly cases?* If delay is observed, in which area is it most common?Denver-II Developmental Screening Test and Alberta Motor Infant Scale were applied to the participants., conditionsModule conditions: Craniosynostosis, Sagittal, conditions: Scaphocephaly, conditions: Developmental Delay, designModule studyType: OBSERVATIONAL, designInfo observationalModel: CASE_ONLY, timePerspective: RETROSPECTIVE, enrollmentInfo count: 21, type: ACTUAL, armsInterventionsModule interventions name: Group 1, outcomesModule primaryOutcomes measure: Denver-II Developmental Screening Test, primaryOutcomes measure: Alberta Infant Motor Scale, eligibilityModule sex: ALL, minimumAge: 2 Months, maximumAge: 17 Months, stdAges: CHILD, contactsLocationsModule locations facility: Acıbadem Altunizade Hospital, city: Istanbul, state: Uskudar, country: Turkey, geoPoint lat: 41.01384, lon: 28.94966, hasResults: False
protocolSection identificationModule nctId: NCT06294613, orgStudyIdInfo id: CIV-23-07-043672, briefTitle: A Prospective, Open-label, Single-center, Study of the ACUSURGICAL Luca System for Treatment of Vitreoretinal Diseases, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-02-08, primaryCompletionDateStruct date: 2024-07, completionDateStruct date: 2024-07, studyFirstPostDateStruct date: 2024-03-05, lastUpdatePostDateStruct date: 2024-03-13, sponsorCollaboratorsModule leadSponsor name: Acusurgical, class: INDUSTRY, descriptionModule briefSummary: Prospective, interventional, open-label, non-controlled, monocentric study in Belgium of Luca, of up to 7 evaluable subjects, undergoing vitreoretinal surgery to treat intravitreal hemorrhage and macular pucker.Only one eye per subject can be enrolled., conditionsModule conditions: Vitreoretinal Disease, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 7, type: ESTIMATED, armsInterventionsModule interventions name: vitreoretinal surgery, outcomesModule primaryOutcomes measure: Safety Outcome, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 85 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: UZ Gent, status: RECRUITING, city: Gent, state: East Flanders, zip: 9000, country: Belgium, contacts name: Bart Leroy, PhD, role: CONTACT, phone: +32 9 33 25791, email: Bart.Leroy@uzgent.be, geoPoint lat: 51.05, lon: 3.71667, hasResults: False